LORINDA LILES: Open Payments
NPI 1104207414 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$999 in 53 payments from 19 companies in 2025. Trend: 2023 $644 · 2024 $1,256 · 2025 $999
Food & beverage: $999
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $282 |
| ANI Pharmaceuticals, Inc. | 4 | $90 |
| Fresenius USA Marketing, Inc. | 4 | $88 |
| OPKO Pharmaceuticals, LLC | 4 | $69 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $60 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $59 |
| Novo Nordisk Inc | 3 | $59 |
| Travere Therapeutics, Inc. | 4 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $42 |
| Aurinia Pharma U.S., Inc. | 2 | $41 |
Products named: Vanrafia, Fabhalta, PURIFIED CORTROPHIN GEL, VELPHORO, RAYALDEE, JARDIANCE, Kerendia, Ozempic.
Industry payments across TX — which companies pay providers there.
